[HTML][HTML] Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure
JR Teerlink, R Diaz, GM Felker… - … England Journal of …, 2021 - Mass Medical Soc
Background The selective cardiac myosin activator omecamtiv mecarbil has been shown to
improve cardiac function in patients with heart failure with a reduced ejection fraction. Its …
improve cardiac function in patients with heart failure with a reduced ejection fraction. Its …
The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose …
Background Many patients with heart failure remain symptomatic and have a poor prognosis
despite existing treatments. Decreases in myocardial contractility and shortening of …
despite existing treatments. Decreases in myocardial contractility and shortening of …
Acute treatment with omecamtiv mecarbil to increase contractility in acute heart failure: the ATOMIC-AHF study
Background: Omecamtiv mecarbil (OM) is a selective cardiac myosin activator that increases
myocardial function in healthy volunteers and in patients with chronic heart failure …
myocardial function in healthy volunteers and in patients with chronic heart failure …
Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study
JR Teerlink, CP Clarke, KG Saikali, JH Lee, MM Chen… - The Lancet, 2011 - thelancet.com
Background Decreased systolic function is central to the pathogenesis of heart failure in
millions of patients worldwide, but mechanism-related adverse effects restrict existing …
millions of patients worldwide, but mechanism-related adverse effects restrict existing …
Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC‐HF baseline characteristics and comparison with contemporary clinical trials
JR Teerlink, R Diaz, GM Felker… - European journal of …, 2020 - Wiley Online Library
Aims The safety and efficacy of the novel selective cardiac myosin activator, omecamtiv
mecarbil, in patients with heart failure with reduced ejection fraction (HFrEF) is being tested …
mecarbil, in patients with heart failure with reduced ejection fraction (HFrEF) is being tested …
Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: rationale and design of GALACTIC-HF
A central factor in the pathogenesis of heart failure (HF) with reduced ejection fraction is the
initial decrease in systolic function. Prior attempts at increasing cardiac contractility with oral …
initial decrease in systolic function. Prior attempts at increasing cardiac contractility with oral …
Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial
Background Impaired contractility is a feature of heart failure with reduced ejection fraction.
We assessed the pharmacokinetics and effects on cardiac function and structure of the …
We assessed the pharmacokinetics and effects on cardiac function and structure of the …
Cardiac myosin activation part 1: from concept to clinic
FI Malik, BP Morgan - Journal of molecular and cellular cardiology, 2011 - Elsevier
Decreased cardiac contractility is a central feature of systolic heart failure and yet we have
no effective drugs to improve cardiac contractility. Existing drugs that increase cardiac …
no effective drugs to improve cardiac contractility. Existing drugs that increase cardiac …
[HTML][HTML] Positive cardiac inotrope omecamtiv mecarbil activates muscle despite suppressing the myosin working stroke
MS Woody, MJ Greenberg, B Barua… - Nature …, 2018 - nature.com
Omecamtiv mecarbil (OM) is a positive cardiac inotrope in phase-3 clinical trials for
treatment of heart failure. Although initially described as a direct myosin activator …
treatment of heart failure. Although initially described as a direct myosin activator …
Effect of omecamtiv mecarbil on exercise capacity in chronic heart failure with reduced ejection fraction: the METEORIC-HF randomized clinical trial
Importance Exercise limitation is a cardinal manifestation of heart failure with reduced
ejection fraction (HFrEF) but is not consistently improved by any of the current guideline …
ejection fraction (HFrEF) but is not consistently improved by any of the current guideline …